1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Glycopyrronium bromide
Trade Name:
Seebri Breezhaler
Manufacturer/Distributor:
Novartis Pharmaceuticals
www.novartis.ca
Classification:
Anticholinergic agent
ATC Class:
R03BB06 - glycopyrronium bromide
Status:
active
Notice of Compliance (yyyy/mm/dd):
2012/10/16
Date Marketed in Canada (yyyy/mm/dd):
2013/01/29
Presentation:
Capsule for inhalation: 50 mcg. DIN: 02394936
Comments:
Novartis is marketing Seebri 50 mcg capsules for the long-term once-daily maintenance bronchodilation in patients with chronic obstructive pulmonary disease (COPD). The capsules are inserted into the Seebri Breezhaler device and the contents are then inhaled.
Back to:
Drug Product Listings 
